RE:RE:This is the Week
Longholder99 wrote: One of these days Norton. You will be correct. Love that the FDA is making results king. Means that when the immuno franken drugs get shelved. The value of TLT's real results just got that much pricier.
That's for sure LH. I haven't felt more confident since Keytruda set the low bar with a 19% durable response rate. I think we all know that % is surmountable. But I think much of the market fails to realize the full value of our ACT. It can not only potentially "replace" primary or SOC treatments, but I believe it has equal (if not greater) potential to be a team player & help boost the efficacy of existing cancer treatments/surgery...that is, being used as a combo or adjuvant therapy. When considering the scarcity of the current competition in the organometallic PS/PDT or x-ray PDT field, I see even more potential.
Imo, Immuno-Franken drugs often underachieve w/o a compatible partner. Though TLD-1433 may prove to be a solo performance star, I wouldn't mind settling now & then for a best supporting role ; ). Good luck...